Pharmalot Ed Silverman STAT Plus: WHO moves to widen access to generic Sovaldi in dozens of countries
Pharmalot Ed Silverman STAT Plus: Gilead faces fresh patent challenges over hepatitis C drugs in India
Health Andrew Joseph Where hepatitis C rates are seven times the US average — and a cure is kept out of reach
Pharmalot Ed Silverman Less than 1 percent of state prisoners with hepatitis C get treated due to drug costs
Don't Miss Bob Tedeschi Where medical specialists are scarce, a push to train primary physicians to do the job
Pharmalot Ed Silverman Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Valeant under criminal investigation for defrauding insurers
Pharmalot Ed Silverman Gilead hep C drug prices blamed for England’s health service rationing treatment
Pharmalot Ed Silverman Gilead won’t have to pay $200 million in patent case because Merck lawyer lied